MAZE
Maze Therapeutics, Inc.
Biotechnology
Market Cap$1.33B
5Y Perf.+51.0%
Build Your Comparison
Side-by-side financial analysisMAZE
RARE
Try popular comparisons:
Stock Comparison
MAZE vs RARE
Revenue, margins, valuation, and 5-year total return — side by side.
RARE
Ultragenyx Pharmaceutical Inc.
Biotechnology
Market Cap$2.36B
5Y Perf.-44.3%
MAZE vs RARE — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  MAZE |  RARE |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $1.33B | $2.36B |
| Revenue (TTM) | $20M | $669M |
| Net Income (TTM) | $-123M | $-609M |
| Gross Margin | 92.0% | 83.6% |
| Operating Margin | -6.7% | -83.9% |
| Total Debt | $23M | $1.28B |
| Cash & Equiv. | $189M | $434M |
MAZE vs RARE — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MAZE
RARE
| Stock | Jan 25 | Jun 26 | Return |
|---|---|---|---|
| Maze Therapeutics, … (MAZE) | 100 | 151.0 | +51.0% |
| Ultragenyx Pharmace… (RARE) | 100 | 55.7 | -44.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MAZE vs RARE
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: MAZE leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. Ultragenyx Pharmaceutical Inc. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
🥇MAZE emerged as the overall leader. Track its performance:
MAZE
Maze Therapeutics, Inc.
The Income Pick
MAZE carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.13
- 51.0% 10Y total return vs RARE's -60.0%
- Lower volatility, beta 1.13, Low D/E 6.6%, current ratio 15.50x
Best for: income & stability and long-term compounding
RARE
Ultragenyx Pharmaceutical Inc.
The Growth Play
RARE is the clearest fit if your priority is growth exposure.
- Rev growth 20.1%, EPS growth 7.3%, 3Y rev CAGR 22.8%
- 20.1% revenue growth vs MAZE's -100.0%
- -91.0% margin vs MAZE's -6.1%
Best for: growth exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  RARE | 20.1% revenue growth vs MAZE's -100.0% |
| Quality / Margins | RARE | -91.0% margin vs MAZE's -6.1% |
| Stability / Safety |  MAZE | Beta 1.13 vs RARE's 1.47 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | MAZE | +88.5% vs RARE's -36.1% |
| Efficiency (ROA) | MAZE | -31.8% ROA vs RARE's -45.8%, ROIC -99.4% vs -89.4% |
MAZE vs RARE — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
FY 2025
MAZE vs RARE — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLMAZELAGGINGRARE
RAREUltragenyx Pharmaceut…
1leads
MAZEMaze Therapeutics, In…
3leads
6 Total Categories
CATEGORYLEADERvs RAREMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RARE3/5
Valuation MetricsMultiples, price ratios, and targets
MAZE1/1
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
MAZE4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
MAZE5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RARE leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RARE is the larger business by revenue, generating $669M annually — 33.5x MAZE's $20M. Profitability is closely matched — net margins range from -91.0% (RARE) to -6.1% (MAZE).
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| RevenueTrailing 12 months | $20M | $669M |
| EBITDAEarnings before interest/tax | -$132M | -$536M |
| Net IncomeAfter-tax profit | -$123M | -$609M |
| Free Cash FlowCash after capex | -$122M | -$487M |
| Gross MarginGross profit ÷ Revenue | +92.0% | +83.6% |
| Operating MarginEBIT ÷ Revenue | -6.7% | -83.9% |
| Net MarginNet income ÷ Revenue | -6.1% | -91.0% |
| FCF MarginFCF ÷ Revenue | -6.1% | -72.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -2.4% |
| EPS Growth (YoY)Latest quarter vs prior year | +39.9% | -17.2% |
RARE leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
MAZE leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Market CapShares × price | $1.3B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $1.2B | $3.2B |
| Trailing P/EPrice ÷ TTM EPS | -7.90x | -4.11x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 3.50x |
| Price / BookPrice ÷ Book value/share | 2.92x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
MAZE leads this category, winning 1 of 1 comparable metric.
Profitability & Efficiency
MAZE leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
MAZE delivers a -36.6% return on equity — every $100 of shareholder capital generates $-37 in annual profit, vs $-6 for RARE.
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| ROE (TTM)Return on equity | -36.6% | -6.1% |
| ROA (TTM)Return on assets | -31.8% | -45.8% |
| ROICReturn on invested capital | -99.4% | -89.4% |
| ROCEReturn on capital employed | -48.1% | -46.4% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.07x | — |
| Net DebtTotal debt minus cash | -$166M | $842M |
| Cash & Equiv.Liquid assets | $189M | $434M |
| Total DebtShort + long-term debt | $23M | $1.3B |
| Interest CoverageEBIT ÷ Interest expense | -148.24x | -14.49x |
MAZE leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
MAZE leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MAZE five years ago would be worth $15,103 today (with dividends reinvested), compared to $2,358 for RARE. Over the past 12 months, MAZE leads with a +88.5% total return vs RARE's -36.1%. The 3-year compound annual growth rate (CAGR) favors MAZE at 14.7% vs RARE's -22.4% — a key indicator of consistent wealth creation.
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| YTD ReturnYear-to-date | -39.4% | +1.6% |
| 1-Year ReturnPast 12 months | +88.5% | -36.1% |
| 3-Year ReturnCumulative with dividends | +51.0% | -53.3% |
| 5-Year ReturnCumulative with dividends | +51.0% | -76.4% |
| 10-Year ReturnCumulative with dividends | +51.0% | -60.0% |
| CAGR (3Y)Annualised 3-year return | +14.7% | -22.4% |
MAZE leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — MAZE and RARE each lead in 1 of 2 comparable metrics.
Risk & Volatility
MAZE is the less volatile stock with a 1.13 beta — it tends to amplify market swings less than RARE's 1.47 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RARE currently trades 56.6% from its 52-week high vs MAZE's 44.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.13x | 1.47x |
| 52-Week HighHighest price in past year | $53.65 | $42.37 |
| 52-Week LowLowest price in past year | $9.83 | $18.29 |
| % of 52W HighCurrent price vs 52-week peak | +44.9% | +56.6% |
| RSI (14)Momentum oscillator 0–100 | 37.0 | 47.5 |
| Avg Volume (50D)Average daily shares traded | 646K | 1.5M |
Evenly matched — MAZE and RARE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MAZE as "Buy" and RARE as "Buy". Consensus price targets imply 162.6% upside for MAZE (target: $63) vs 101.7% for RARE (target: $48).
| Metric | MAZEMaze Therapeutics… | RAREUltragenyx Pharma… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $63.25 | $48.36 |
| # AnalystsCovering analysts | 6 | 33 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
MAZE leads in 3 of 6 categories (Valuation Metrics, Profitability & Efficiency). RARE leads in 1 (Income & Cash Flow). 1 tied.
Best OverallMaze Therapeutics, Inc. (MAZE)Leads 3 of 6 categories
Loading custom metrics...
MAZE vs RARE: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MAZE or RARE a better buy right now?
For growth investors, Ultragenyx Pharmaceutical Inc.
(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -100. 0% for Maze Therapeutics, Inc. (MAZE). Analysts rate Maze Therapeutics, Inc. (MAZE) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MAZE or RARE?
Over the past 5 years, Maze Therapeutics, Inc.
(MAZE) delivered a total return of +51. 0%, compared to -76. 4% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: MAZE returned +51. 0% versus RARE's -60. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MAZE or RARE?
By beta (market sensitivity over 5 years), Maze Therapeutics, Inc.
(MAZE) is the lower-risk stock at 1. 13β versus Ultragenyx Pharmaceutical Inc. 's 1. 47β — meaning RARE is approximately 30% more volatile than MAZE relative to the S&P 500.
04Which is growing faster — MAZE or RARE?
By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.
(RARE) is pulling ahead at 20. 1% versus -100. 0% for Maze Therapeutics, Inc. (MAZE). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -40. 2% for Maze Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MAZE or RARE?
Ultragenyx Pharmaceutical Inc.
(RARE) is the more profitable company, earning -85. 4% net margin versus -612. 7% for Maze Therapeutics, Inc. — meaning it keeps -85. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RARE leads at -79. 5% versus -670. 3% for MAZE. At the gross margin level — before operating expenses — MAZE leads at 92. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MAZE or RARE?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MAZE or RARE better for a retirement portfolio?
For long-horizon retirement investors, Maze Therapeutics, Inc.
(MAZE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 13)). Both have compounded well over 10 years (MAZE: +51. 0%, RARE: -60. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MAZE and RARE?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MAZE is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.